Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kenneth Reed

Dermatology Quincy, MA Medical Doctor

NPI 1295775732 CMS profile 286231

104 Quarry St Ste 2, Quincy, MA 02169

Open in the dashboard

General payments

$208,313

380 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$8,098 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Kenneth Reed of Quincy, MA is reported in the CMS Open Payments database as having received $208,313 across 380 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $8,098 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $482 17
2024 General $979 32
2023 General $28,800 3
2022 General $46,176 8
2021 General $45,961 96
2020 General $74,799 62
2019 General $11,116 162

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kenneth Reed
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Kenneth Reed were reported at $482. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Kenneth Reed Dermatology median Middle half National median
2019 $11,116 $454 $129–$1,240 $163
2020 $74,799 $235 $81–$756 $114
2021 $45,961 $377 $108–$1,108 $132
2022 $46,176 $514 $143–$1,391 $149
2023 $28,800 $607 $159–$1,674 $160
2024 $979 $751 $204–$1,903 $164
2025 $482 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. RedHill Biopharma Inc. $192,767 21 payments
  2. Ortho Dermatologics, a division of Bausch Health US, LLC $6,979 19 payments
  3. AbbVie, Inc. $2,145 91 payments
  4. Helsinn Therapeutics (U.S.), Inc. $1,479 3 payments
  5. Novartis Pharmaceuticals Corporation $960 58 payments
  6. Janssen Biotech, Inc. $817 37 payments
  7. Lilly USA, LLC $529 24 payments
  8. Pfizer Inc. $447 27 payments
  9. LEO Pharma Inc. $421 20 payments
  10. Genzyme Corporation $327 14 payments
  11. Other $1,442 66 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $162,970 16 payments
  2. Consulting Fee $28,890 1 payment
  3. Food and Beverage $7,590 352 payments
  4. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $5,820 3 payments
  5. Travel and Lodging $2,957 6 payments
  6. Education $86 2 payments
Products named General payments · program years 2019–2025
  1. DUOBRII $6,904 14 payments
  2. VALCHLOR $1,479 3 payments
  3. SKYRIZI $1,288 51 payments
  4. HUMIRA $991 47 payments
  5. TREMFYA $546 21 payments
  6. TALTZ $529 24 payments
  7. COSENTYX Immunology $456 27 payments
  8. STELARA $444 23 payments
  9. ENSTILAR $366 18 payments
  10. COSENTYX Dermatology $337 24 payments
  11. Other $3,840 195 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$85,094

Medicare's payments for the services billed

Medicare patients

136

Average age 76

Services billed

380

59 women, 77 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 46%
Chronic kidney disease 25%
Ischemic heart disease 24%
Diabetes 23%
Atrial fibrillation 23%
Depression 18%
Cancer 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $388
$388 — —
RINVOQ
  • AbbVie, Inc. $119
$119 — —
TREMFYA
  • Janssen Biotech, Inc. $107
$107 — —
Bimzelx
  • UCB, Inc. $57
$57 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $55
$55 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

380 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record